BAX and cancer: Thus, small molecule based therapy targeting p53 [37] and/or Bax [38] regulatory proteins may be one possible way to prevent from eventual undesired secondary effects in normal tissues after bortezomib treatment, without interfering with the desired anti-cancer effect.